Risk Communication Advisory Committee; Notice of Meeting, 16427 [2011-6788]
Download as PDF
Federal Register / Vol. 76, No. 56 / Wednesday, March 23, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Risk Communication Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
jlentini on DSKJ8SOYB1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Risk
Communication Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on May 5, 2011, from 8 a.m. to
5 p.m.
Location: Food and Drug
Administration, 5630 Fishers Lane,
Conference Room, rm. 1066, Rockville,
MD 20857.
Contact Person: Lee L. Zwanziger,
Office of Policy, Planning and Budget,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 32, rm.
3278, Silver Spring, MD 20993–0002,
301–796–9151, FAX: 301–847–8611,
e-mail: RCAC@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.
Agenda: On May 5, 2011, the
committee will hear and discuss
developments in FDA’s ongoing
communications programs. The
discussion will focus on the use of
different channels for information
dissemination, tracking how
information is gathered and spread, and
thoughts on reaching less accessible
target audiences.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
VerDate Mar<15>2010
16:46 Mar 22, 2011
Jkt 223001
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before April 29, 2011. Oral
presentations from the public will be
scheduled between approximately
1 p.m. and 2 p.m. on May 5, 2011.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before April 21, 2011. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 22, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Lee L.
Zwanziger at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act
(5 U.S.C. app. 2).
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
16427
Dated: March 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–6788 Filed 3–22–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
Memorandum of Agreement Between
the Indian Health Service and the
Department of Interior; Bureau of
Indian Affairs and Bureau of Indian
Education
AGENCY:
ACTION:
Indian Health Service, HHS.
Notice.
The Indian Health Service
(IHS) is providing notice of a
Memorandum of Agreement (MOA)
between the IHS and the Department of
the Interior (DOI), signed in 2009, and
has developed an amendment to that
MOA that includes language consistent
with Section 703 of the Indian Health
Care Improvement Act (IHCIA), Public
Law 94–437, as amended. The purpose
of the MOA and the amendment is to
advance our partnership with Tribes
and Federal stakeholders on alcohol and
substance abuse prevention and
treatment. The Patient Protection and
Affordable Care Act’s, Public Law 111–
148, permanent authorization of the
Indian Health Care Improvement Act
(IHCIA) establishes timelines and
requirements for coordinated actions by
the Department of Interior (DOI), the
Department of Health and Human
Services (HHS), Tribes and Tribal
organizations. Specifically, Section 703
of the IHCIA provides new authorities
that permit the DOI and HHS, acting
through the Indian Health Service (IHS),
to develop and enter into a
Memorandum of Agreement (MOA), or
review and update any existing
memoranda of agreement, as required by
Section 4205 of the Indian Alcohol and
Substance Abuse Prevention and
Treatment Act of 1986 (25 U.S.C.2411).
DOI and IHS signed an MOA on this
topic in 2009, and have developed an
amendment to that MOA that includes
language consistent with the new IHCIA
provision. In accordance with Section
703 of the IHCIA, which states that the
MOA between the IHS and DOI shall be
published in the Federal Register, the
agency is publishing notice of this MOA
and the amendment to this MOA.
SUMMARY:
The original MOA was effective
on December 12, 2009. The amendment
is effective March 1, 2011.
DATES:
E:\FR\FM\23MRN1.SGM
23MRN1
Agencies
[Federal Register Volume 76, Number 56 (Wednesday, March 23, 2011)]
[Notices]
[Page 16427]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-6788]
[[Page 16427]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0002]
Risk Communication Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Risk Communication Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on May 5, 2011, from 8 a.m.
to 5 p.m.
Location: Food and Drug Administration, 5630 Fishers Lane,
Conference Room, rm. 1066, Rockville, MD 20857.
Contact Person: Lee L. Zwanziger, Office of Policy, Planning and
Budget, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
32, rm. 3278, Silver Spring, MD 20993-0002, 301-796-9151, FAX: 301-847-
8611, e-mail: RCAC@fda.hhs.gov, or FDA Advisory Committee Information
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and
follow the prompts to the desired center or product area. Please call
the Information Line for up-to-date information on this meeting. A
notice in the Federal Register about last minute modifications that
impact a previously announced advisory committee meeting cannot always
be published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site and call the appropriate
advisory committee hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On May 5, 2011, the committee will hear and discuss
developments in FDA's ongoing communications programs. The discussion
will focus on the use of different channels for information
dissemination, tracking how information is gathered and spread, and
thoughts on reaching less accessible target audiences.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
April 29, 2011. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. on May 5, 2011. Those
individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the general
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
April 21, 2011. Time allotted for each presentation may be limited. If
the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by April 22, 2011.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Lee L. Zwanziger at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: March 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-6788 Filed 3-22-11; 8:45 am]
BILLING CODE 4160-01-P